Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAURA 2: osimertinib with or without platinum + pemetrexed as first-line treatment for EGFR-mutated advanced non-small cell lung cancer
CTR20200679Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib, pemetrexed, cisplatin, carboplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200679.